Health Care·Pharmaceuticals·$6.1B
Terns Pharmaceutical is a healthcare company focused on developing innovative therapies for patients with serious diseases. With a market cap of $6 billion, it operates in the pharmaceuticals industry, which is critical for advancing medical treatments and improving patient outcomes.
EPS (Earnings Per Share)
EPS is a key indicator of profitability and will show how well the company is managing its expenses relative to its revenues.
Revenue Growth
Although revenue estimates are not available, any indication of revenue growth would signal market acceptance of Terns' products.
Wall Street expectations, options signals, track record, and call prep available with Pro.
EPS Beat Streak
0Q
EPS Beat Rate
88%
Avg EPS Surprise
-20.48%
Avg Stock Reaction
+0.97%
In Q4 2025, Terns reported an EPS of -$1.03, which was significantly below expectations, leading to a slight decline in stock price. The company did not provide revenue figures, leaving investors uncertain about its financial health.
Management Promises & Guidance
Investors are cautious ahead of Terns' earnings report, especially given the significant EPS miss last quarter. Without analyst estimates or management guidance, expectations are uncertain.
Bull Case
If Terns can demonstrate improved operational efficiency and better-than-expected EPS, it could regain investor confidence and see a positive stock reaction.
Bear Case
Continued losses and lack of revenue transparency could lead to further declines in stock price, especially if the company fails to provide clear guidance.
EPS (Earnings Per Share)
N/AEPS is a key indicator of profitability and will show how well the company is managing its expenses relative to its revenues.
Revenue Growth
N/AAlthough revenue estimates are not available, any indication of revenue growth would signal market acceptance of Terns' products.
The print will turn on these two things.
Q1
What will the EPS be for Q1-2026?
Given the significant miss last quarter, the EPS figure will be crucial in assessing the company's financial trajectory and operational improvements.
Q2
Will Terns provide any revenue guidance or updates on product development?
Investors are looking for clarity on revenue potential and product pipeline, which could significantly impact future growth prospects.
Why consensus could be wrong
The Street may be underestimating Terns' potential for operational improvement, especially given its high EPS beat rate in the past.
Supporting Evidence
Terns has beaten EPS estimates 88% of the time in the last eight quarters, indicating potential for positive surprises.
Despite the recent miss, the stock has shown resilience with modest gains following previous earnings beats.
Management's previous commentary hinted at ongoing efforts to streamline operations, which could lead to improved results.
Key Risk
If EPS comes in better than -$0.80, it could challenge the current bearish sentiment.
Pre-commit to what would confirm each case.
The market is weighing the potential for recovery in earnings against the backdrop of previous misses and lack of revenue transparency.
Bull Confirmed If
An EPS improvement to -$0.80 or better would suggest operational progress and could validate the bull case.
Bear Confirmed If
An EPS worse than -$1.00 would reinforce concerns about the company's financial health.
Implied Move
±N/A
There is no available options market data to gauge investor sentiment ahead of the earnings report.
Likely market behavior by outcome — not investment advice.
Beat & Raise
If Terns beats expectations with a significant EPS improvement, history suggests the stock could rise by around +1.12% on the following day, confirming a positive trend.
In-Line / Cautious
If results are in line with expectations but lack strong guidance, the stock may remain flat or see a modest reaction as investors digest the news.
Miss
Should Terns miss expectations again, history suggests a slight decline of around -0.08%, which could further erode investor confidence.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
PARAMOUNT SKYDANCE C Class B
May 4, 2026